Summary
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Conference.
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation treatment.
Pulse Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 4 | $86 | $151.6 | $65.6 | 76.28% |
| NA Nizar Araji National Bank Of Canada /FI/ | 508 | $3,960.62 | $21,544.28 | $17,583.66 | 443.96% |
 Point72 Asset Management LP Point72 Asset Management LP | 106,457 | $2.95M | $4.74M | $1.79M | 60.62% |
 Joseph Castro Nuveen LLC | 101,683 | $2.29M | $4.22M | $1.93M | 84.25% |
 Ana-Maria Ignat Covestor Ltd | 20 | $554.6 | $848.2 | $293.6 | 52.94% |
Pulse Biosciences, Inc. (PLSE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pulse Biosciences, Inc. ever had a stock split?
Pulse Biosciences, Inc. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Paul Arthur LaViolette CEO | NASDAQ (CM) Exchange | 74587B101 CUSIP |
| US Country | 116 Employees | - Last Dividend | - Last Split | 18 May 2016 IPO Date |
Overview
Pulse Biosciences, Inc. is a pioneering bioelectric medicine company, previously known as Electroblate, Inc. until its name change in December 2015. Founded in 2014, the company has quickly positioned itself at the forefront of medical technology innovation with its headquarters in Hayward, California. The company's core mission revolves around developing novel therapeutic devices that leverage its unique Nano-Pulse Stimulation (NPS) technology. This technology represents a significant advancement in treating a broad spectrum of medical conditions by delivering nano-second pulses of electrical energy directed at targeted cells. Unlike traditional methods, this approach ensures the non-thermal destruction of cells while preserving adjacent non-cellular tissues, marking a new era in precision medicine.
Products and Services
The cornerstone of Pulse Biosciences’ offering is the CellFX System. This platform embodies the practical application of Nano-Pulse Stimulation technology in clinical settings. Details of the product include:
- CellFX System: A tunable, software-enabled, console-based platform designed for precision. It harnesses the power of nano-second duration pulses of electrical energy. The system's unique capability to non-thermally clear targeted cells without damaging adjacent non-cellular tissue addresses a vast array of medical conditions. Its versatility and efficacy position it as a revolutionary tool in the field of bioelectric medicine.
